In the third quarter, Commonwealth Equity Services LLC reduced its holding in Novo Nordisk by 49.9%, selling 237,049 shares and retaining just 237,978 shares by period end. This divestiture represents one of the largest position changes among reporting institutions, as evidenced in the firm’s latest 13F filing. The reduction follows a broader trend of portfolio rebalancing among asset managers, with Novo Nordisk now accounting for a notably smaller portion of Commonwealth’s equity allocation. Other institutional investors, including True Wealth Design LLC and NewSquare Capital LLC, also adjusted positions—some increasing stakes by over 100%—highlighting mixed sentiment in the quarter.

Novo Nordisk reported third-quarter earnings per share of $1.02, surpassing consensus estimates by $0.25, driven by strong sales volume in its GLP-1 franchise. However, reported revenue of $11.79 billion fell short of the projected $11.98 billion, reflecting pricing pressures and regional reimbursement challenges. The company’s net margin remained robust at 32.8%, supported by ongoing manufacturing efficiencies and tight cost controls. Return on equity stood at an exceptional 73.5%, underscoring the high profitability of the core diabetes and obesity care portfolio despite the slight top-line miss.

Following the quarterly release, brokerages have maintained a mixed consensus on Novo Nordisk’s shares. Among twenty-three analysts surveyed, one rates the stock at a strong buy, seven assign a buy rating and eleven recommend holding, while four advise selling. Recent research notes emphasize the sustainability of the GLP-1 growth runway balanced against potential market saturation risks and increasing competition. The average analyst price target implies limited near-term upside, but most expect earnings and free cash flow to remain resilient over the next twelve months, driven by pipeline expansions and geographic sales diversification.